Home > What We Do > Participate in a Clinical Trial

Australian Alzheimer’s Research FOUNDATION is currently seeking participants for the following trials:

Study NAME AND WHO IS ELIGIBLE

Hoffmann-La Roche – GRADuate Phase 3
WA only

This study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with prodromal Alzheimer’s Disease.

Who can be involved:

  • Male or female, aged 50 to 90 years
  • Has an identified, reliable, study partner (who spends 10+ hours a week with the subject)
  • Must have mild cognitive impairment due to Alzheimer’s disease or diagnosed with Alzheimer’s dementia

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

What is involved:

  • Monthly visits
  • Monthly medication (subcutaneous injection)
  • 28 month duration

Novartis Pharmaceuticals – Generation Phase 2/3
WA only

To test whether an investigational drug called CNP250, administered daily, can slow down the onset and progression of clinical symptoms associated with Alzheimer’s disease in participants at risk of the development of Alzheimer’s disease based on age and genotype.

Who can be involved:

  • Male or female, aged 60 to 75 years
  • Does not have a current medical or neurological condition that might impact cognition or performance on cognitive assessments
  • Has an identified, reliable, study partner

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

What is involved:

  • 4 visits per year
  • 12 month duration for genetic disclosure then 3-5 year study duration
  • Medication will be administered intramuscularly or orally depending on the cohort

ANAVEX2-73-AD – Phase 2b/3
WA only

This is a Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. To assess the safety and efficacy of ANAVEX2-73 for the treatment of early Alzheimer’s disease.

Who can be involved:

  • Male or female, aged 60 – 85 years
  • Must be diagnosed with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
  • Has an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

What is involved:

  • Monthly visits
  • 12 months duration
  • Daily medication (oral tablet)

Australian Alzheimer’s Research Foundation – TotAL Study Phase 2
Testosterone Study
NSW & WA only

This study aims to evaluate the impact of testosterone alone or in combination with fish oil on amyloid load in the brain, as well as whether it affects performance on tests of memory, cognition and function.

Who can be involved:

  • Males aged 60 to 80 years
  • Have memory concerns
  • Does not have a current medical or neurological condition
  • Not currently taking testosterone or diagnosed with hypogonadism
  • Western Australia and New South Wales residents

For further information please contact

WA Contact: Shane Fernandez, Study Coordinator on Ph: 08 6304 3957 or Email: s.fernandez@ecu.edu.au

NSW Contact: Deepal Wakade, Clinical Trial Coordinator on Ph: 02 9812 2974 or Email: deepal.wakade@mq.edu.au

What is involved:

  • 18 month duration
  • Most visits 8 weeks apart
  • Testosterone/placebo will be administered intramuscularly every 8 weeks and fish oil/placebo taken orally every day
  • Medical examinations, memory tests, brain scans, and cerebrospinal fluid collection

Sleep Study
WA only

This study aims to examine whether improved sleep (better or longer) contributes to better memory and thinking, and improved markers of brain health (assessed using brain imaging). The study will implement a non-pharmacological intervention to improve sleep in older adults who are ‘poor sleepers.

Who can be involved:

  • Male and females aged 60 years and over
  • Residents from Western Australia

For further information about the Sleep Study please contact Manja Laws, Research Assistant on 08 6457 0264 or email m.laws@ecu.edu.au

* Please note that participants in all studies may have a chance of being placed on a placebo medication